142 related articles for article (PubMed ID: 31483053)
1. Elevated expression of G protein-coupled receptor 30 (GPR30) is associated with poor prognosis in patients with uterine cervical adenocarcinoma.
Ino Y; Akimoto T; Takasawa A; Takasawa K; Aoyama T; Ueda A; Ota M; Magara K; Tagami Y; Murata M; Hasegawa T; Saito T; Sawada N; Osanai M
Histol Histopathol; 2020 Apr; 35(4):351-359. PubMed ID: 31483053
[TBL] [Abstract][Full Text] [Related]
2. GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer.
Arias-Pulido H; Royce M; Gong Y; Joste N; Lomo L; Lee SJ; Chaher N; Verschraegen C; Lara J; Prossnitz ER; Cristofanilli M
Breast Cancer Res Treat; 2010 Aug; 123(1):51-8. PubMed ID: 19902352
[TBL] [Abstract][Full Text] [Related]
3. Estrogen/GPR30 Signaling Contributes to the Malignant Potentials of ER-Negative Cervical Adenocarcinoma via Regulation of Claudin-1 Expression.
Akimoto T; Takasawa A; Takasawa K; Aoyama T; Murata M; Osanai M; Saito T; Sawada N
Neoplasia; 2018 Oct; 20(10):1083-1093. PubMed ID: 30227306
[TBL] [Abstract][Full Text] [Related]
4. Mesothelin and GPR30 staining among a spectrum of pancreatic epithelial neoplasms.
Glass JP; Parasher G; Arias-Pulido H; Donohue R; Prossnitz ER; Cerilli LA
Int J Surg Pathol; 2011 Oct; 19(5):588-96. PubMed ID: 21632639
[TBL] [Abstract][Full Text] [Related]
5. The G protein-coupled estrogen receptor (GPER/GPR30) may serve as a prognostic marker in early-stage cervical cancer.
Friese K; Kost B; Vattai A; Marmé F; Kuhn C; Mahner S; Dannecker C; Jeschke U; Heublein S
J Cancer Res Clin Oncol; 2018 Jan; 144(1):13-19. PubMed ID: 28924735
[TBL] [Abstract][Full Text] [Related]
6. Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression.
Filardo EJ; Graeber CT; Quinn JA; Resnick MB; Giri D; DeLellis RA; Steinhoff MM; Sabo E
Clin Cancer Res; 2006 Nov; 12(21):6359-66. PubMed ID: 17085646
[TBL] [Abstract][Full Text] [Related]
7. Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer.
Sjöström M; Hartman L; Grabau D; Fornander T; Malmström P; Nordenskjöld B; Sgroi DC; Skoog L; Stål O; Leeb-Lundberg LM; Fernö M
Breast Cancer Res Treat; 2014 May; 145(1):61-71. PubMed ID: 24715381
[TBL] [Abstract][Full Text] [Related]
8. GPR30: a novel indicator of poor survival for endometrial carcinoma.
Smith HO; Leslie KK; Singh M; Qualls CR; Revankar CM; Joste NE; Prossnitz ER
Am J Obstet Gynecol; 2007 Apr; 196(4):386.e1-9; discussion 386.e9-11. PubMed ID: 17403429
[TBL] [Abstract][Full Text] [Related]
9. Expression of CD133, PAX2, ESA, and GPR30 in invasive ductal breast carcinomas.
Liu Q; Li JG; Zheng XY; Jin F; Dong HT
Chin Med J (Engl); 2009 Nov; 122(22):2763-9. PubMed ID: 19951611
[TBL] [Abstract][Full Text] [Related]
10. G-protein-coupled estrogen receptor GPER-1 expression in hormone receptor-positive breast cancer is associated with poor benefit of tamoxifen.
Ignatov T; Claus M; Nass N; Haybaeck J; Seifert B; Kalinski T; Ortmann O; Ignatov A
Breast Cancer Res Treat; 2019 Feb; 174(1):121-127. PubMed ID: 30478785
[TBL] [Abstract][Full Text] [Related]
11. Plasma membrane expression of G protein-coupled estrogen receptor (GPER)/G protein-coupled receptor 30 (GPR30) is associated with worse outcome in metachronous contralateral breast cancer.
Tutzauer J; Sjöström M; Bendahl PO; Rydén L; Fernö M; Leeb-Lundberg LMF; Alkner S
PLoS One; 2020; 15(4):e0231786. PubMed ID: 32302351
[TBL] [Abstract][Full Text] [Related]
12. Transmembrane estrogen receptor GPR30 is more frequently expressed in malignant than benign ovarian endometriotic cysts and correlates with MMP-9 expression.
Long L; Cao Y; Tang LD
Int J Gynecol Cancer; 2012 May; 22(4):539-45. PubMed ID: 22495744
[TBL] [Abstract][Full Text] [Related]
13. Heregulin-β1-induced GPR30 upregulation promotes the migration and invasion potential of SkBr3 breast cancer cells via ErbB2/ErbB3-MAPK/ERK pathway.
Ruan SQ; Wang ZH; Wang SW; Fu ZX; Xu KL; Li DB; Zhang SZ
Biochem Biophys Res Commun; 2012 Apr; 420(2):385-90. PubMed ID: 22425775
[TBL] [Abstract][Full Text] [Related]
14. GPR30 predicts poor survival for ovarian cancer.
Smith HO; Arias-Pulido H; Kuo DY; Howard T; Qualls CR; Lee SJ; Verschraegen CF; Hathaway HJ; Joste NE; Prossnitz ER
Gynecol Oncol; 2009 Sep; 114(3):465-71. PubMed ID: 19501895
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of G-protein-coupled estrogen receptor-30 in human myometrial and uterine leiomyoma smooth muscle.
Tian R; Wang Z; Shi Z; Li D; Wang Y; Zhu Y; Lin W; Gui Y; Zheng XL
Fertil Steril; 2013 Jan; 99(1):256-263.e3. PubMed ID: 23043685
[TBL] [Abstract][Full Text] [Related]
16. Nuclear G protein-coupled oestrogen receptor (GPR30) predicts poor survival in patients with ovarian cancer.
Zhu CX; Xiong W; Wang ML; Yang J; Shi HJ; Chen HQ; Niu G
J Int Med Res; 2018 Feb; 46(2):723-731. PubMed ID: 29239277
[TBL] [Abstract][Full Text] [Related]
17. Nuclear estrogen receptor-mediated Notch signaling and GPR30-mediated PI3K/AKT signaling in the regulation of endometrial cancer cell proliferation.
Wei Y; Zhang Z; Liao H; Wu L; Wu X; Zhou D; Xi X; Zhu Y; Feng Y
Oncol Rep; 2012 Feb; 27(2):504-10. PubMed ID: 22075757
[TBL] [Abstract][Full Text] [Related]
18. [The expression of a novel estrogen receptor, GPR30, in epithelial ovarian carcinoma and its correlation with MMP-9].
Liu HD; Yan Y; Cao XF; Tan PZ; Wen HX; Lv CM; Li XM; Liu GY
Sheng Li Xue Bao; 2010 Dec; 62(6):524-8. PubMed ID: 21170498
[TBL] [Abstract][Full Text] [Related]
19. Expression and prognostic significance of estrogen and progesterone receptors in adenocarcinoma of the uterine cervix. An immunocytochemical study.
Masood S; Rhatigan RM; Wilkinson EW; Barwick KW; Wilson WJ
Cancer; 1993 Jul; 72(2):511-8. PubMed ID: 8319181
[TBL] [Abstract][Full Text] [Related]
20. GPR30 is overexpressed in post-puberal testicular germ cell tumors.
Franco R; Boscia F; Gigantino V; Marra L; Esposito F; Ferrara D; Pariante P; Botti G; Caraglia M; Minucci S; Chieffi P
Cancer Biol Ther; 2011 Mar; 11(6):609-13. PubMed ID: 21278491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
